- Home
- Publications
- Publication Search
- Publication Details
Title
PARP inhibitors as precision medicine for cancer treatment
Authors
Keywords
-
Journal
National Science Review
Volume 4, Issue 4, Pages 576-592
Publisher
Oxford University Press (OUP)
Online
2017-03-15
DOI
10.1093/nsr/nwx027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety
- (2016) U. A. Matulonis et al. ANNALS OF ONCOLOGY
- An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors
- (2016) Ahmad Awada et al. ANTI-CANCER DRUGS
- 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
- (2016) Ruoxi Hong et al. BMC CANCER
- Erratum: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
- (2016) Yvette Drew et al. BRITISH JOURNAL OF CANCER
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours
- (2016) Kan Yonemori et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Abstract CT149: Assessment of the cardiac safety of veliparib in a thorough QT/QTc study at therapeutic doses in patients with relapsed/refractory solid tumors: a randomized, placebo-controlled crossover study
- (2016) Wijith Munasinghe et al. CANCER RESEARCH
- The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
- (2016) Y. Wang et al. CANCER RESEARCH
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness
- (2016) Vijayalakshmi Kari et al. EMBO REPORTS
- Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib
- (2016) Andrew J. Wilson et al. GYNECOLOGIC ONCOLOGY
- Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer
- (2016) Min Zhang et al. GYNECOLOGIC ONCOLOGY
- Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
- (2016) Dong Wang et al. GYNECOLOGIC ONCOLOGY
- A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187
- (2016) Eric X. Chen et al. INVESTIGATIONAL NEW DRUGS
- TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity
- (2016) Pavel Moudry et al. JOURNAL OF CELL BIOLOGY
- Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
- (2016) Pierre Chabot et al. JOURNAL OF NEURO-ONCOLOGY
- Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
- (2016) Yi Du et al. NATURE MEDICINE
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair
- (2016) E-B Choi et al. ONCOGENE
- An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
- (2016) J. Mateo et al. Targeted Oncology
- Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
- (2016) Dong Wang et al. Oncotarget
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
- (2016) Robert J. Cardnell et al. PLoS One
- Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer
- (2015) J. Bendell et al. ANNALS OF ONCOLOGY
- Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
- (2015) Oreekha Amin et al. BMC CANCER
- PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers
- (2015) Jennifer Stanley et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)
- (2015) Hidenori Mizugaki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
- (2015) S.-W. Tang et al. CLINICAL CANCER RESEARCH
- A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix
- (2015) Charles Kunos et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
- (2015) Hsin-Wei Liao et al. JOURNAL OF CLINICAL INVESTIGATION
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
- (2015) J. Shen et al. Cancer Discovery
- Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
- (2015) J. Watkins et al. Cancer Discovery
- Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity
- (2015) Jessica Frankum et al. Oncotarget
- Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment
- (2015) Laura R. H. Ip et al. Oncotarget
- The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
- (2015) José Luis Ordóñez et al. Oncotarget
- HP1β Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy
- (2015) Young-Ho Lee et al. PLoS One
- Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness
- (2015) Pradip De et al. NEOPLASIA
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
- (2014) S. Novello et al. ANNALS OF ONCOLOGY
- Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
- (2014) Edwin Choy et al. BMC CANCER
- Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer
- (2014) Felix Y. Feng et al. BREAST CANCER RESEARCH AND TREATMENT
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
- (2014) Carey Anders et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
- (2014) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer
- (2014) Jetzabel García-Parra et al. EUROPEAN JOURNAL OF CANCER
- Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
- (2014) Maha Hussain et al. INVESTIGATIONAL NEW DRUGS
- Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors
- (2014) Poorval M. Joshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program:PALB2mutation predicts exceptionalin vivoresponse to BMN 673
- (2014) Malcolm A. Smith et al. PEDIATRIC BLOOD & CANCER
- The road from next-generation sequencing to personalized medicine
- (2014) Manuel L Gonzalez-Garay Personalized Medicine
- Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
- (2014) Selvi Durmus et al. PHARMACEUTICAL RESEARCH
- Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
- (2014) Romana Koppensteiner et al. PLoS One
- Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib
- (2014) Marine Gilabert et al. PLoS One
- PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
- (2014) Y. Hu et al. Cancer Discovery
- Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
- (2013) E H Lips et al. BRITISH JOURNAL OF CANCER
- EGFR-Activating Mutations Correlate with a Fanconi Anemia-like Cellular Phenotype That Includes PARP Inhibitor Sensitivity
- (2013) H. N. Pfaffle et al. CANCER RESEARCH
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
- (2013) J. E. Ang et al. CLINICAL CANCER RESEARCH
- Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer
- (2013) R. J. Cardnell et al. CLINICAL CANCER RESEARCH
- Identification of miRNA modulators to PARP inhibitor response
- (2013) Sari Neijenhuis et al. DNA REPAIR
- A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer
- (2013) Joyce F. Liu et al. EUROPEAN JOURNAL OF CANCER
- Beyond DNA repair, the immunological role of PARP-1 and its siblings
- (2013) Maria Manuela Rosado et al. IMMUNOLOGY
- Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues
- (2013) Moritz Birkelbach et al. Journal of Thoracic Oncology
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
- (2013) M. Ihnen et al. MOLECULAR CANCER THERAPEUTICS
- A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
- (2013) S Postel-Vinay et al. ONCOGENE
- PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells
- (2013) Payel Chatterjee et al. PLoS One
- Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
- (2012) Anneleen Daemen et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
- (2012) E Dean et al. BRITISH JOURNAL OF CANCER
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition
- (2012) P. Kalev et al. CANCER RESEARCH
- PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
- (2012) H. Cheng et al. CARCINOGENESIS
- PARPs and the DNA damage response
- (2012) F. G. Sousa et al. CARCINOGENESIS
- Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1
- (2012) Sean Vance et al. CELL CYCLE
- A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
- (2012) S. Kummar et al. CLINICAL CANCER RESEARCH
- A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
- (2012) A. Rajan et al. CLINICAL CANCER RESEARCH
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
- (2012) A. G. Patel et al. CLINICAL CANCER RESEARCH
- CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells
- (2012) R. H. G. Wright et al. GENES & DEVELOPMENT
- On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
- (2012) X. Luo et al. GENES & DEVELOPMENT
- High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer
- (2012) Frederick Klauschen et al. HISTOPATHOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Histone ADP-Ribosylation Facilitates Gene Transcription by Directly Remodeling Nucleosomes
- (2012) R. Martinez-Zamudio et al. MOLECULAR AND CELLULAR BIOLOGY
- Drug candidates derailed in case of mistaken identity
- (2012) Heidi Ledford NATURE
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
- (2012) S Yoshikawa et al. ONCOGENE
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA
- (2012) S. Volinia et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents
- (2012) Wenrui Duan et al. Translational Research
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Signaling Mechanism of Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Inflammatory Diseases
- (2011) Xueqing Ba et al. AMERICAN JOURNAL OF PATHOLOGY
- ADP-ribose polymers localized on Ctcf–Parp1–Dnmt1 complex prevent methylation of Ctcf target sites
- (2011) Michele Zampieri et al. BIOCHEMICAL JOURNAL
- A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
- (2011) O A Khan et al. BRITISH JOURNAL OF CANCER
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
- (2011) J. Chad Brenner et al. CANCER CELL
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas
- (2011) S. Kummar et al. CANCER RESEARCH
- A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors*,†
- (2011) Noboru Yamamoto et al. CANCER SCIENCE
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- (2011) X. Liu et al. CLINICAL CANCER RESEARCH
- Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study
- (2011) Jens Samol et al. INVESTIGATIONAL NEW DRUGS
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer
- (2011) Ian Paul et al. JOURNAL OF PATHOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
- (2011) Neil Johnson et al. NATURE MEDICINE
- Methodological and practical challenges for personalized cancer therapies
- (2011) Ignacio I. Wistuba et al. Nature Reviews Clinical Oncology
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage
- (2011) H. C. Kang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition
- (2010) Tony Sourisseau et al. EMBO Molecular Medicine
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
- (2010) Rémi Buisson et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
- (2009) Feng Zhang et al. CURRENT BIOLOGY
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- SIRT1 Promotes Cell Survival under Stress by Deacetylation-Dependent Deactivation of Poly(ADP-Ribose) Polymerase 1
- (2009) S. B. Rajamohan et al. MOLECULAR AND CELLULAR BIOLOGY
- Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
- (2009) X. Liu et al. MOLECULAR CANCER RESEARCH
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler
- (2009) A. J. Gottschalk et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP-ribose)-Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1
- (2009) D. Ahel et al. SCIENCE
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
- (2008) Christopher J. Lord et al. DNA REPAIR
- CCCTC-binding Factor Activates PARP-1 Affecting DNA Methylation Machinery
- (2008) Tiziana Guastafierro et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Proteomic Investigation of Phosphorylation Sites in Poly(ADP-ribose) Polymerase-1 and Poly(ADP-ribose) Glycohydrolase
- (2008) Jean-Philippe Gagné et al. JOURNAL OF PROTEOME RESEARCH
- The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor
- (2008) N. Godin-Heymann et al. MOLECULAR CANCER THERAPEUTICS
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now